Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy
Considering the occurrence of several actionable alterations including a <i>TPM4:NTRK1</i> fusion reported herein, these results support the use of next-generation sequencing (NGS) including RNA analysis for fusion detection to identify such alterations in patients with MPTs. These findings highlight the importance of comprehensive NGS in MPT research to uncover potential targeted treatment options for these patients.
Authors
- Jennifer R. Ribeiro (ORCID: https://orcid.org/0000-0002-1685-8568)
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Antoinette R. Tan (ORCID: https://orcid.org/0000-0002-7895-7000)
- Tolulope Adeyelu (ORCID: https://orcid.org/0000-0003-0615-0731)
- Andrew Elliott (ORCID: https://orcid.org/0000-0001-8494-8031)
- Matthew James Oberley (ORCID: https://orcid.org/0000-0001-6419-2513)
- Juneko E. Grilley‐Olson (ORCID: https://orcid.org/0000-0002-1896-7020)
- Stephanie L. Graff (ORCID: https://orcid.org/0000-0003-1928-1722)
- George W. Sledge (ORCID: https://orcid.org/0000-0003-0297-0775)
- Jane Meisel (ORCID: https://orcid.org/0000-0002-2642-865X)
- Rani Bansal (ORCID: https://orcid.org/0000-0002-1342-4692)
- Laura Horst Rosenberger (ORCID: https://orcid.org/0000-0002-6829-6747)
Institutions
- Emory University (US)
- Providence College (US)
- Brown University (US)
- Levine Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- Caris Life Sciences (United States) (US)
- Lifespan (US)
- Duke University Hospital (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1200/po.24.00289
- Citations
- 10
- Primary Topic
- Breast Lesions and Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 4.25
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Relay Therapeutics
- Seagen
- Foundation Medicine
- Daiichi Sankyo Europe